IL1RL1 and chronic myelogenous leukemia, BCR-ABL1 positive: ST2 overexpression is regularized after imatinib mesylate treatment, while IL-33 neutralizes in vitro imatinib mesylate-induced proliferation arrest in CML CD34 progenitors through activation of the STAT5 pathway.